Abstract Body

Here, we investigate the pathways by which maraviroc-treated cohorts experience improved mucosal immunity through changes in host:microbial interactions. We hypothesize that maraviroc therapy-induced improvements in mucosal immunity impacts the microbial mucosal interaction through either a change in the distribution of the microbial communities, their metabolic state, or both.

We previously performed a three-arm, randomized clinical trial (RCT) that examined the impact of maraviroc alone or combined with raltegravir versus efavirenz (each combined with emtricitabine-tenofovir DF) on gastrointestinal-associated lymphoid tissue (GALT) immune reconstitution. Subjects who were naïve to antiretroviral therapy and with CCR5-tropic virus underwent upper endoscopy and flexible sigmoidoscopy before and 9 months after initiating treatment; plasma and fecal samples were also collected at these time points. We performed 16S rRNA sequencing to look first at the composition of the microbial communities in all samples before and after treatment with the regimens tested in the recently completed RCT. Metabolomic analysis of the stool and plasma was performed to explore whether alterations in the metabolic state of the microbial community is a potential mechanism for altering mucosal immune lymphocyte distribution or immune function as has been suggested for other diseases of the gastrointestinal tract that lead to systemic inflammation.

Analysis of 16S rRNA sequencing of the samples yielded clearly distinct microbial communities between body sites. Interestingly, the microbial communities remained stable in each of the body sites before and after 9 months of each treatment. Despite the overall community stability, with metabolomics analysis we identified distinct functional profiles between treatment groups and over time.

Extensive analysis of the microbial community profiles of the HIV-positive cohort show no community-level differences between treatment groups. Due to the immune reconstitution we see in maraviroc-treated patients, we expected instead to see variation in the functional profile of these microbial communities. We performed metabolomics analysis of these samples to explore the functional output of these stable microbial communities and we determined the metabolic pathways by which maraviroc-treated cohorts achieve improved mucosal immunity.